BNF:

4.1.1

Status:

Do Not Prescribe (DNP), Grey - after consultant/specialist recommendation, Grey - after consultant/specialist initiation

Decision Date:

October 2013

Comments

GREY after consultant/specialist initiation: 

• for use in children with neurodevelopment disorders and CAMHS patients (including off-label use). See Melatonin information sheet
• Melatonin MR 2mg tablets and Adaflex tablets are the preferred melatonin preparations. (Decision date - March/July/September 2022, June 2023)
• Circadin is a choice for those who require half a melatonin 2mg MR tablet whilst still retaining its modified release properties, or for those who may have medical reasons that make it difficult to switch (e.g. autism). (Decision date - June 2023)
• For other preparations including liquids when it is not possible to use crushed tablets, see Specials guidance

GREY after consultant/specialist recommendation:

• for REM sleep for dementia with Lewy bodies and Parkinson's Disease dementia (off-label use). See managing behavioural problems in patients with dementia.  (Decision date - April 2023)

 GREY:

•  not recommended except in exceptional circumstances for its licensed indication in patients over 55. 

DO NOT PRESCRIBE (DNP): Melatonin 1mg/ml oral SF solution

• For short-term treatment of jet-lag disorder in adults
• Not suitable for children under 6 years of age due to safety concerns regarding propylene glycol content. (Decision date - August 2019/October 2022)

DO NOT PRESCRIBE (DNP): 

• Slenyto prolonged release tablets (pending a national review) (Decision date - May 2019)
• Melatonin for treating sleep disorders in adults who are blind. (Decision date - September 2021)

search again